Acorda Therapeutics discloses new results from MS-F202 phase 2 clinical study

By Elaine Rigoli

Tampa, Fla., April 17 - Acorda Therapeutics, Inc. said results from a new evaluation of certain data from the MS-F202 phase 2 clinical study, completed in 2004, show that among subjects with consistently improved walking speeds during treatment, leg strength was also improved.

Data from the MS-F202 study were analyzed for potential interaction between observed changes in lower extremity muscle strength, as assessed by the modified British Medical Research Council manual muscle testing procedures, referred to as the lower extremity manual muscle test and improvements in walking speed, measured with the timed 25-foot walking test.

The Fampridine-SR timed-walk responder group, pooling all three dose groups (10 mg, 15 mg and 20 mg taken twice per day), showed significant improvement in leg strength compared to the placebo group, indicating that leg strength was also improved, according to a news release.

The Fampridine-SR timed walk non-responder group also had significantly improved leg strength compared to the placebo group, suggesting that Fampridine-SR may also have benefits for patients who do not experience a consistent improvement in walking speed with treatment, the release said.

Similar results were seen comparing only the 10 mg-treated group to the placebo-treated group.

Based in Hawthorne, N.Y., Acorda is a biotechnology company developing therapies to restore neurological function in people with spinal cord injury, multiple sclerosis and related conditions of the nervous system.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.